Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a
multi-year supply agreement with Laboratory Corporation of America®
Holdings (LabCorp®) (NYSE: LH). The agreement gives LabCorp expanded
rights to use Illumina next-generation sequencing (NGS) and microarray
equipment and supplies to develop, validate and introduce
laboratory-developed tests to clinicians in the United States and Canada.
Under the terms of the agreement, LabCorp will be able to purchase a
broader range of Illumina products for the development of new diagnostic
tools in multiple specialties, including genetic testing, oncology,
transplant medicine and forensics, in addition to other applications.
LabCorp is currently using the technology in connection with new human
leukocyte antigen (HLA) tests that it plans to introduce this year.
"The Illumina next-generation sequencing platform gives LabCorp the
flexibility to develop a wide range of molecular tests," said Dr. Mark
Brecher, LabCorp's Chief Medical Officer. "The HLA typing assays we are
developing on Illumina's family of NG platforms will provide physicians
with the ability to more accurately match bone marrow donors to
"We are excited to support LabCorp's ability to offer more NGS-based
tests such as its HLA offering," said Nicholas J. Naclerio, Illumina's
Senior Vice President of Corporate & Venture Development. "Illumina is
committed to making NGS broadly available for clinical laboratory
testing, and this agreement with LabCorp significantly expands the
number of clinicians and patients who will have access to improved
diagnostic tools and information."
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
[ Back To NFVZone's Homepage ]